Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04957082 · ClinicalTrials.gov registry record · NA
Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake
A NA study of SARS CoV 2 Infection, sponsored by Michigan State University.
- Completed
- Registry status
- NA
- Development phase
- 666
- Enrollment target
- 1
- Study location
NCT04957082: Completed NA study of SARS CoV 2 Infection, sponsored by Michigan State University.
NCT04957082 is a NA study of SARS CoV 2 Infection that has completed, run by Michigan State University. The registered enrollment target is 666 participants, below the 4,169-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04957082, a NA study of SARS CoV 2 Infection, has completed, sponsored by Michigan State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 666 participants
- Enrollment target
- 1
- Study location
Study Summary
This disparities-focused study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among African Americans residing in Flint, Michigan. This iteration will consider individuals recruited from the Flint Registry and assess willingness to participate in a drive-up saliva sample collection taking place at a central location in Flint, Michigan.
Primary Outcome
Number (Percentage) of participants who respond "yes" to be included in offer to participate in no cost SAR-CoV-2 salivary antibody test.
Conditions Studied
Interventions
- BEHAVIORAL Culturally Targeted SARS-CoV-2 Communication
- BEHAVIORAL General SARS-CoV-2 Communication
Study Locations (1)
Michigan
- Flint Journal Building - Flint
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 666 participants |
| Start Date | 2021-08-04 |
| Est. Completion | 2022-12-19 |
| Phase | NA |
What the finished NCT04957082 record still lists
NCT04957082 is an interventional study that assigns participants to a tested intervention. The registered 666 participants enrollment target is mid-sized for trials with a published cap, below the 4,169-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (84% lower).
The record links to 1 condition, with SARS CoV 2 Infection appearing as the primary indexed condition, and to 2 interventions - of which Culturally Targeted SARS-CoV-2 Communication is the first listed.
NCT04957082 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04957082 about?
NCT04957082 is a clinical study titled "Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake". This disparities-focused study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among African Americans residing in Flint, Michigan. This iteration will consider individuals recruited from the Flint Registry and assess...
What is the current status of trial NCT04957082?
This trial is currently completed. It is a NA study. The enrollment target is 666 participants. The study started on 2021-08-04. Estimated completion is 2022-12-19.
What conditions does trial NCT04957082 study?
This clinical trial studies the following conditions: SARS CoV 2 Infection.
What interventions are being tested in trial NCT04957082?
The interventions under investigation include: Culturally Targeted SARS-CoV-2 Communication (BEHAVIORAL), General SARS-CoV-2 Communication (BEHAVIORAL).
Who is sponsoring clinical trial NCT04957082?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04957082 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS CoV 2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04957082's enrollment target sits among peer trials
666 14th of 35 higher than 22 of 35 other SARS CoV 2 Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS CoV 2 Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
RECRUITING · NA
-
Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos
ACTIVE NOT RECRUITING · NA
-
Safe and Healthy Schools
COMPLETED · NA
-
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
RECRUITING
-
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
- NCT06981078 · 666 participants · Phase 2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT04155034 · 668 participants · Phase 3
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI